Vimarsana
Biggest News Aggregation in the World

Page 4 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

AstraZeneca : Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours -April 05, 2024 at 08:38 pm EDT - Vimarsana News

AstraZeneca : Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours -April 05, 2024 at 08:38 pm EDT

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showed clinically meaningful responses across a broad range of tumours ...

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - Vimarsana News

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors

This is the fifth indication for fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo and AstraZeneca) approved by the FDA.

AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer - Vimarsana News

AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer

Cambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or...

Tagrisso plus chemo approved in U.S. for lung cancer - Vimarsana News

Tagrisso plus chemo approved in U.S. for lung cancer

The FDA greenlit the Tagrisso/chemo regimen in treatment-naive EGFR-mutant NSCLC, bolstering AstraZeneca’s flagship brand against would-be rivals.

AstraZeneca Shares Top FTSE 100 Index Risers After Tagrisso Gets U.S. Approval - Vimarsana News

AstraZeneca Shares Top FTSE 100 Index Risers After Tagrisso Gets U.S. Approval

By Ian Walker AstraZeneca shares are up and leading the FTSE 100 index risers after the company said that its lung-cancer treatment Tagrisso, together with...